Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Keytruda (Pembrolizumab) | Lung Cancer

Merck’s Drug Keytruda for Treatment of NSCLC

Posted on May 10, 2015
Post Views: 2,509

Keytruda (Pembrolizumab)Lung cancer is one of the most serious types of cancer and it is a malignant lung tumor caused by out of control cell growth. It can start in the windpipe, the main airway or the lung tissue. Lung cancer kills nearly 160,000 Americans annually and the most common form of disease is NSCLC.

UCLA researchers have found that Merck & Co’s Keytruda is safe and effective in arresting tumor growth of patients with advanced non-small cell lung cancer. Keytruda, also known as pembrolizumab, belongs to a class of immunotherapies known as PD-1 inhibitors that block the Programmed Death receptor on tumor cells. This drug helps the immune system to prevent the occurrence of lung cancer by blocking protein known as PD-1 or PD-L1.

Merck’s conducted a study of 495 patients with NSCLC and found that 45% of patients with high levels of PD-L1 responded to Keytruda. Patients with PD-L1 below 1% the response rate was 10.7%. According to the researchers a quarter of trial patients had PD-1 in at least 50% of their tumor cells and overall, 19% of trial patients responded to the drug. These results were presented at a meeting of American Association for Cancer Research.

Dr. Roger Perlmutter, president, Merck Research Laboratories said, “In this study, NSCLC patients whose tumors express PD-L1 in the majority of their cells experienced the highest response rates to KEYTRUDA treatment. The results from this study formed the basis for our Breakthrough Therapy designation and our recent FDA submission for advanced NSCLC, and indicate that tumor PD-L1 expression may be a relevant biomarker to identify patients more likely to have higher rates of response to KEYTRUDA in this tumor type.”

Edward Garon, researcher at David Geffen School of Medicine, University of California said in response to the ORR of the entire study was 19.4% as “one of the exciting outcomes with this class of drug.”

Merck is advancing a clinical development program for Keytruda across more than 30 tumor types and over 14000 patients in more than 85 clinical trials.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d